Precision, Translation and Microfluidics – What is Nanotherapy Coming To?
Dr. Claudia Dos Santos
Professor of Medicine and Staff Critical Care Intensivist
Temerty Faculty of Medicine, University of Toronto and Unity Health Toronto
Date: Friday, September 20, 2024
Time: 1–2 p.m. EDT
Host: TBD
Location: In-person and virtual
Li Ka Shing Knowledge Institute, Auditorium, and via Zoom
Refreshments will be served.
Lecture Takeaways
The main takeaways are as follows:
- The applications of microfluidics in precision medicine.
- What was learned from the COVID-19 pandemic and the advancements in RNA-based Therapeutics.
- How Clinicians and Bioengineers meet in the middle and work together to solve clinical challenges.
Biography
Claudia Dos Santos is a Professor of Medicine at the Temerty Faculty of Medicine with a clinical appointment as a Staff Critical Care Intensivist at Unity Health Toronto (UHT), a university hospital affiliated with the University of Toronto. Dr. Dos Santos currently holds the Pitts Research Chair in Acute Care and Emergency Medicine and is a scientist at the Keenan Research Centre for Biomedical Science. Her research focuses on building a world-class program in translational molecular critical care, with three distinct areas of expertise: 1) patient-based discovery (omics/bioinformatics); 2) in-vitro mechanistic research (cell models); and 3) in-vivo preclinical research (transgenic animal models). Dr. Dos Santos is a past Scientific Director of the Canadian Critical Care Society and Co-Director of the Centre for Research and Applications in Fluidic Technologies (CRAFT), a collaboration between the University of Toronto, the National Research Council of Canada, and UHT. She established the Critical Care Medicine Biobank at Unity Health and leads the PREcision meDIcine for CriTical Care (PREDICT) program, which aims to advance translational molecular critical care through precision diagnostics, machine learning, and artificial intelligence. She is also the project lead for ARIATNE (Advanced RNA-Intelligence for Accelerated Therapeutic Nanoparticle Engineering), a collaboration with the Nanomedicine Innovation Network (NMIN) that seeks to translate knowledge gained from PREDICT into personalized RNA therapies for rapid infection response and pandemic preparedness.
No sign-up is required. For more information, contact the iBEST coordinator at ibest@torontomu.ca.
